ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

OM vs MRK // EV/EBITDA & P/E VALUATION

Outset Medical Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: OM 2 — MRK 7
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OM VS. MRK) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC OM MRK SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 39.10% 74.80% -35.70 MRK /gross-margins <GO>
Return on Invested Capital (ROIC) -28.00% 20.70% -48.70 MRK /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 15.3x — TIE /valuation <GO>
Free Cash Flow Yield — 3.42% — TIE /fcf-yield <GO>
Operating Margin -55.80% 34.30% -90.10 MRK /operating-margins <GO>
Net Profit Margin -60.00% 28.10% -88.10 MRK /net-margins <GO>
Revenue Growth (YoY) 5.10% 1.30% +3.80 OM /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.26% -2.26 MRK /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.19 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 6/9 7/9 -1.00 MRK /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 55.8 51.7 +4.10 OM /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.92 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 18.4x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $78.8M $361.02B -$360.94B MRK /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR OM REV MRK REV OM GROSS % MRK GROSS % OM FCF MRK FCF
FY 2025 $119.5M $65.01B 39.1% 74.8% -$47.1M $12.36B
FY 2024 $113.7M $64.17B 33.9% 76.3% -$117.2M $18.10B
FY 2023 $130.4M $60.12B — — -$131.4M $10.30B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OM // BETA —
MRK // BETA 0.92